Prescription drug · ANDA
Tazarotene NDC 51672-1374
Tazarotene 1 mg/g · Cream · Topical · Sun Pharmaceutical Industries, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 51672-1374-2 | 5167213740251672137402 | 1 TUBE in 1 CARTON (51672-1374-2) / 30 g in 1 TUBEMarketed from Apr 3, 2017 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tazarotene
- Generic name (nonproprietary)
- tazarotene
- Active ingredients
- Tazarotene — 1 mg/g
- Dosage form
- Cream
- Route
- Topical
- Labeler
- Sun Pharmaceutical Industries, Inc.NDC labeler code 51672
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 208258
- Marketing start
- Listing expires
- Other FDA classes
- Retinoids (Chemical structure)
- Identifiers
- Product ID 51672-1374_39620f25-787e-f51b-e063-6294a90a36deSPL ID 39620f25-787e-f51b-e063-6294a90a36deSPL set ID 34d79c31-1568-4797-a4f5-31200c7788dbRxCUI 313200UNII 81BDR9Y8PS
- Pharmacologic class
- Retinoid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N451672137402followed by a unit qualifier and the quantityPackage 51672-1374-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. Tazarotene cream, 0.1% is a retinoid indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper- and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. ( 1 ) Limitations of Use: Does not eliminate or prevent wrinkles or restore more youthful skin. ( 1 ) Does not repair sun damaged skin or reve…
Excerpt only. Read the full label for complete information.
About NDC 51672-1374
- What is NDC 51672-1374?
- 51672-1374 is the product NDC for Tazarotene, Tazarotene 1 mg/g cream, listed with the FDA by Sun Pharmaceutical Industries, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Tazarotene.
- What is the active ingredient?
- Tazarotene.
- Who is the labeler?
- Sun Pharmaceutical Industries, Inc., NDC labeler code 51672. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Tazarotene?
- 14 other product NDCs are listed under this name. See all Tazarotene NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Tazarotene products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Tazarotene | Tazarotene .5 mg/g | CreamTopical | Cosette Pharmaceuticals, Inc. | 0713-0765 | 00713-0765-3100713-0765-60 |
| Tazarotene | Tazarotene .5 mg/g | GelCutaneous | Solaris Pharma Corporation | 73473-309 | 73473-0309-1073473-0309-30 |
| Tazarotene | Tazarotene 1 mg/g | GelCutaneous | Solaris Pharma Corporation | 73473-310 | 73473-0310-1073473-0310-30 |
| Tazarotene | Tazarotene .5 mg/g | CreamTopical | Padagis Israel Pharmaceuticals Ltd | 45802-706 | 45802-0706-9445802-0706-96 |
| Tazarotene | Tazarotene .5 mg/g | CreamTopical | Bryant Ranch Prepack | 72162-2420 | 72162-2420-0372162-2420-06 |
| Tazarotene | Tazarotene .5 mg/g | GelTopical | Padagis Israel Pharmaceuticals Ltd | 45802-436 | 45802-0436-0145802-0436-94 |
| Tazarotene | Tazarotene 1 mg/g | GelTopical | Padagis Israel Pharmaceuticals Ltd | 45802-442 | 45802-0442-0145802-0442-94 |
| Tazarotene | Tazarotene 1 mg/g | GelTopical | Bryant Ranch Prepack | 72162-2202 | 72162-2202-03 |
| Tazarotene | Tazarotene 1 mg/g | GelTopical | Cosette Pharmaceuticals, Inc. | 0713-0804 | 00713-0804-3100713-0804-99 |
| Tazarotene | Tazarotene .5 mg/g | GelTopical | Cosette Pharmaceuticals, Inc. | 0713-0805 | 00713-0805-3100713-0805-99 |
Other NDCs under ANDA 208258
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tazarotene | Tazarotene 1 mg/g | CreamTopical | Sun Pharmaceutical Industries, Inc. | 51672-1373 |